UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...

Checkpoint Inhibition in Non-Hodgkin's Lymphoma

Oncology research and treatment, 2017, Vol.40 (11), p.662-672

Heß, Georg

2017

Link zum Volltext

Verfügbarkeit prüfen

Ibrutinib for the treatment of relapsed/refractory mantle cell lymphoma: extended 3.5-year follow up from a pooled analysis

Haematologica (Roma), 2019-05, Vol.104 (5), p.e211-e214

2019

Link zum Volltext

Verfügbarkeit prüfen

Utility of presepsin (sCD14-ST) as a diagnostic and prognostic marker of sepsis in the emergency department

Clinica chimica acta, 2015-10, Vol.450, p.169-175

2015

Link zum Volltext

Verfügbarkeit prüfen

Phase III Study to Evaluate Temsirolimus Compared With Investigator's Choice Therapy for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

Journal of clinical oncology, 2009-08, Vol.27 (23), p.3822-3829

2009

Link zum Volltext

Verfügbarkeit prüfen

The Bruton tyrosine kinase inhibitor ibrutinib abrogates triggering receptor on myeloid cells 1-mediated neutrophil activation

Haematologica (Roma), 2017-05, Vol.102 (5), p.e191-e194

2017

Link zum Volltext

Verfügbarkeit prüfen

Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial

The Lancet. Haematology, 2016-05, Vol.3 (5), p.e217-e227

2016

Link zum Volltext

Verfügbarkeit prüfen

Idelalisib impairs TREM-1 mediated neutrophil inflammatory responses

Scientific reports, 2018-04, Vol.8 (1), p.5558-10, Article 5558

2018

Link zum Volltext

Verfügbarkeit prüfen

Panel of three novel serum markers predicts liver stiffness and fibrosis stages in patients with chronic liver disease

PloS one, 2017-03, Vol.12 (3), p.e0173506-e0173506

2017

Link zum Volltext

Verfügbarkeit prüfen

What is the best time for psychosocial counselling from the perspective of cancer patients and their relatives? A multi‐centre qualitative study

Counselling and psychotherapy research, 2022-09, Vol.22 (3), p.558-568

2022

Link zum Volltext

Verfügbarkeit prüfen

Temsirolimus for the treatment of mantle cell lymphoma

Expert review of hematology, 2009-12, Vol.2 (6), p.631-640

Hess, Georg

2009

Link zum Volltext

Verfügbarkeit prüfen

Clinical activity of abemaciclib in patients with relapsed or refractory mantle cell lymphoma - a phase II study

Haematologica (Roma), 2021-03, Vol.106 (3), p.859-862

2021

Link zum Volltext

Verfügbarkeit prüfen

Prognosis of patients with primary central nervous system lymphoma after high-dose chemotherapy followed by autologous stem cell transplantation

Haematologica (Roma), 2013-05, Vol.98 (5), p.765

2013

Link zum Volltext

Verfügbarkeit prüfen

Targeting Bcl-2 family proteins modulates the sensitivity of B-cell lymphoma to rituximab-induced apoptosis

Blood, 2008-10, Vol.112 (8), p.3312-3321

2008

Link zum Volltext

Verfügbarkeit prüfen

Safety of AFM11 in the treatment of patients with B-cell malignancies: findings from two phase 1 studies

Trials, 2023-01, Vol.24 (1), p.4-4, Article 4

2023

Link zum Volltext

Verfügbarkeit prüfen

Correction: Panel of three novel serum markers predicts liver stiffness and fibrosis stages in patients with chronic liver disease

PloS one, 2017-06, Vol.12 (6), p.e0179205-e0179205

2017

Link zum Volltext

Verfügbarkeit prüfen

Long‐term Outcomes With Ibrutinib Treatment for Patients With Relapsed/Refractory Mantle Cell Lymphoma: A Pooled Analysis of 3 Clinical Trials With Nearly 10 Years of Follow‐up

HemaSphere, 2022-05, Vol.6 (5), p.e712-n/a

2022

Link zum Volltext

Verfügbarkeit prüfen

The role of stem cell transplantation in follicular lymphoma

Best practice & research. Clinical haematology, 2018-03, Vol.31 (1), p.31-40

Hess, Georg

2018

Link zum Volltext

Verfügbarkeit prüfen

Chemotherapiefreie Behandlung indolenter Lymphome: Hype oder Hope?

Der Onkologe, 2019-10, Vol.25 (10), p.859-866

2019

Link zum Volltext

Verfügbarkeit prüfen

Life-threatening disseminated enterovirus infection during combined rituximab and ibrutinib maintenance treatment for mantle cell lymphoma: a case report

Journal of medical case reports, 2020-08, Vol.14 (1), p.135-135, Article 135

2020

Link zum Volltext

Verfügbarkeit prüfen

Identification of a genetic signature enriching for response to ibrutinib in relapsed/refractory follicular lymphoma in the DAWN phase 2 trial

Cancer medicine (Malden, MA), 2022-01, Vol.11 (1), p.61-73

2022

Link zum Volltext

Verfügbarkeit prüfen

Outcome of COVID‐19 in Patients With Mantle Cell Lymphoma—Report From the European MCL Registry

HemaSphere, 2022-05, Vol.6 (5), p.e0711-n/a

2022

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 643

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(511)
Mit Volltextzugriff
(581)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Checkpoint Inhibition in Non-Hodgkin's Lymphoma

Ibrutinib for the treatment of relapsed/refractory mantle cell lymphoma: extended 3.5-year follow up from a pooled analysis

Utility of presepsin (sCD14-ST) as a diagnostic and prognostic marker of sepsis in the emergency department

Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study

Phase III Study to Evaluate Temsirolimus Compared With Investigator's Choice Therapy for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

The Bruton tyrosine kinase inhibitor ibrutinib abrogates triggering receptor on myeloid cells 1-mediated neutrophil activation

Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial

Safety and Clinical Activity of a Combination Therapy Comprising Two Antibody-Based Targeting Agents for the Treatment of Non-Hodgkin Lymphoma: Results of a Phase I/II Study Evaluating the Immunoconjugate Inotuzumab Ozogamicin With Rituximab

Idelalisib impairs TREM-1 mediated neutrophil inflammatory responses

Panel of three novel serum markers predicts liver stiffness and fibrosis stages in patients with chronic liver disease

What is the best time for psychosocial counselling from the perspective of cancer patients and their relatives? A multi‐centre qualitative study

Temsirolimus for the treatment of mantle cell lymphoma

Clinical activity of abemaciclib in patients with relapsed or refractory mantle cell lymphoma - a phase II study

Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas

Prognosis of patients with primary central nervous system lymphoma after high-dose chemotherapy followed by autologous stem cell transplantation

Targeting Bcl-2 family proteins modulates the sensitivity of B-cell lymphoma to rituximab-induced apoptosis

Safety of AFM11 in the treatment of patients with B-cell malignancies: findings from two phase 1 studies

Correction: Panel of three novel serum markers predicts liver stiffness and fibrosis stages in patients with chronic liver disease

Long‐term Outcomes With Ibrutinib Treatment for Patients With Relapsed/Refractory Mantle Cell Lymphoma: A Pooled Analysis of 3 Clinical Trials With Nearly 10 Years of Follow‐up

The role of stem cell transplantation in follicular lymphoma

Chemotherapiefreie Behandlung indolenter Lymphome: Hype oder Hope?

Kinetics of Renal Function during Induction in Newly Diagnosed Multiple Myeloma: Results of Two Prospective Studies by the German Myeloma Study Group DSMM

Life-threatening disseminated enterovirus infection during combined rituximab and ibrutinib maintenance treatment for mantle cell lymphoma: a case report

Identification of a genetic signature enriching for response to ibrutinib in relapsed/refractory follicular lymphoma in the DAWN phase 2 trial

Outcome of COVID‐19 in Patients With Mantle Cell Lymphoma—Report From the European MCL Registry

Suchergebnisse filtern